Skip to content
Peptide Insider

Naturally occurring tripeptide–copper complex

GHK-Cu

Also known as Copper tripeptide-1 · Glycyl-L-histidyl-L-lysine copper(II) · GHK · Copper peptide

Preclinical ResearchLIMITEDFDA approved: No

GHK is a tripeptide — glycine, histidine, lysine — that occurs naturally in human plasma and binds copper(II) with high affinity. It was identified in 1973 in work on why plasma from young donors behaved differently from plasma from older donors in tissue culture, and it has been studied ever since as a signal involved in tissue remodelling. Its plasma concentration declines with age, which is the origin of most of the longevity framing around it. GHK-Cu is unusual in this field for two reasons: it is a genuinely endogenous molecule rather than a synthetic construct, and it is already in widespread lawful use as a cosmetic ingredient. What it does not have is a substantial body of randomised controlled clinical trials.

Written by Peptide Insider Editorial TeamPublished Last reviewed

The Insider Summary

What it is
A naturally occurring human tripeptide (Gly-His-Lys) complexed with copper. Present in plasma, saliva and urine; concentrations decline with age.
Why researchers are interested
Broad-spectrum effects on gene expression and extracellular matrix biology. Gene-profiling work reports that GHK modulates a very large fraction of human genes, with effects concentrated in tissue remodelling, antioxidant defence and DNA repair pathways.
Evidence
Limited. The mechanistic and gene-expression literature is substantial and the cosmetic-science literature is large, but adequately powered randomised controlled trials with clinical endpoints are scarce, and the most cited review explicitly calls for clinical studies rather than reporting them.
Regulatory status
Not an approved drug. Copper tripeptide-1 is used lawfully as a cosmetic ingredient in topical products, which is a different regulatory category with a much lower evidentiary bar. FDA lists GHK-Cu among substances whose 503A compounding nominations were withdrawn.
Bottom line
GHK-Cu has the most credible *mechanism* of any compound in the consumer peptide space and one of the weakest *clinical trial* records. Topical cosmetic use is well established and low-risk; claims about systemic injection, hair regrowth or longevity run well ahead of the published evidence.

Quick reference

Compound
Peptide-copper complex
Research areas
Skin & Dermatology ResearchTissue & Recovery ResearchLongevity Research
Evidence level
LIMITED
Research status
Preclinical Research
FDA approved
No
Human clinical evidence
Limited
Sequence
Gly-His-Lys (complexed with copper(II))
Last reviewed
17 September 2026

What is GHK-Cu?

GHK-Cu is a complex of a naturally occurring human tripeptide with copper. The peptide sequence — glycine, histidine, lysine — is short enough to synthesise trivially and is present endogenously in human plasma, where its concentration falls substantially between early adulthood and later life.

This endogeneity is what separates GHK-Cu from most compounds discussed on this site. It is not a designed analog of a hormone; it is a molecule the body already makes, being supplied from outside. That changes the nature of the safety question — the body has machinery for handling it — without answering the efficacy question, which remains largely open outside of topical cosmetic use.

It matters that copper is part of the molecule. Copper is an essential trace element with a narrow window between sufficiency and toxicity, and any discussion of systemic administration has to account for the copper as well as the peptide.

What is GHK-Cu being studied for?

Skin and extracellular matrix. The largest research line. Studies report increased synthesis of collagen and other matrix components by dermal fibroblasts, with a body of cosmetic-science literature on topical formulations. This is also the only context in which GHK-Cu is in routine lawful use.

Wound healing. Animal and cell-culture work reports improved repair in dermal wound models, consistent with the matrix-remodelling mechanism.

Gene expression and ageing biology. The most-cited modern work is analytical rather than clinical: profiling which genes GHK modulates, and mapping those onto pathways involved in DNA repair, antioxidant defence and tumour suppression [1]. The authors of that review note that clinical studies had not been conducted and argue that they should be — a framing worth keeping in mind whenever this literature is cited as evidence of clinical benefit.

Hair. Copper peptides appear frequently in hair products. The published controlled evidence for hair outcomes is thin, and readers should treat before-and-after imagery from product marketing as marketing.

How does GHK-Cu work?

GHK binds copper(II) and is thought to act partly as a physiological copper carrier, delivering the ion to enzymes that require it, and partly as a direct signalling molecule. Reported activities include stimulation of collagen, elastin, decorin and glycosaminoglycan synthesis by dermal fibroblasts, modulation of matrix metalloproteinases and their inhibitors, and antioxidant effects. Gene-profiling analyses reported by Pickart and Margolina describe GHK modulating a very large proportion of human genes at a 50% or greater change threshold, stimulating roughly 59% and suppressing roughly 41% of those affected [1]. Findings of that scale are striking, and they are also the kind of result that needs independent replication before it can bear much weight.

Research and clinical evidence

The table below grades the published record separately for each research area, because a compound can be well studied in one context and entirely unstudied in another. Grades follow the Peptide Insider evidence taxonomy.

Evidence level by research area
Research areaEvidence levelWhat the published record shows
Topical skin remodelling and cosmetic useLIMITEDA substantial cosmetic-science and mechanistic literature, but few adequately powered randomised controlled trials with blinded clinical endpoints.
Wound healingPRECLINICALCell-culture and animal wound models report accelerated repair and matrix synthesis.
Gene expression, antioxidant and anti-cancer pathwaysPRECLINICALGene-profiling and in vitro work only. The principal review in this area explicitly calls for clinical studies to be conducted, rather than reporting them.
Hair growthINSUFFICIENTWidely marketed, sparsely studied. We have not identified robust randomised controlled trials supporting hair outcomes.

Laboratory and in vitro research

Work in cells or isolated tissue. Useful for mechanism, not for predicting clinical effect.

Skin regenerative and anti-cancer actions of copper peptides (review and gene-expression analysis)[1]

2018
Design
Narrative review incorporating gene-expression profiling data

FindingsReports that GHK-Cu modulates a very large fraction of human genes at a 50% or greater change threshold, upregulating apoptosis-related, DNA-repair and tumour-suppressor genes and downregulating several cancer-associated genes. Also summarises wound-healing, antioxidant and growth-factor findings.

LimitationsA review rather than primary controlled research, written by the peptide’s principal proponents. Gene-expression change is not a clinical outcome. The authors themselves state that clinical studies have not been carried out.

No qualifying human clinical studies. We have not identified published, controlled human trials of this compound for the research areas described above. That absence is the most important fact on this page.

FDA and regulatory status

GHK-Cu is not an approved drug in the United States and has no FDA-approved indication.

It occupies a different regulatory space from most compounds on this site: as copper tripeptide-1, it is used lawfully as an ingredient in topical cosmetic products. Cosmetics in the US are regulated for safety and labelling rather than efficacy, and a cosmetic ingredient is not permitted to be marketed with claims that it treats or prevents disease. The presence of GHK-Cu in a legitimate skincare product therefore says nothing about whether it works for any medical purpose.

FDA lists GHK-Cu among the substances nominated for the section 503A bulk drug substances list whose nominations were withdrawn [2].

Safety and known risks

Risks are separated into what is documented, what is plausible but unestablished, and what has not been studied. The third column is usually the longest one for an unapproved compound, and it is not a reassurance.

Known risks

Documented in regulatory labelling or published trial safety data.

  • Topical copper peptide formulations are generally well tolerated in cosmetic use; irritation and contact sensitivity are the commonly reported issues.

Potential risks

Plausible on mechanism or drug-class grounds, but not established for this compound.

  • Copper is an essential trace element with a narrow margin between sufficiency and excess. Any route that delivers meaningful systemic copper raises questions that topical use does not.
  • Effects on gene expression as broad as those reported in vitro would, if they occurred systemically in humans, be difficult to predict in either direction.

Unknown or insufficiently studied

Questions the published record does not currently answer.

  • Systemic pharmacokinetics in humans following exogenous administration are not well characterised in the published literature.
  • Long-term safety of sustained systemic exposure is unstudied.
  • Effects in people with disorders of copper handling have not been studied.

Frequently asked questions

Is GHK-Cu natural?
Yes. GHK is a tripeptide that occurs naturally in human plasma, saliva and urine, and it binds copper physiologically. Plasma concentrations decline with age. Being endogenous is not the same as being proven effective when supplied from outside the body.
Does GHK-Cu have clinical trial evidence?
Very little. The literature is dominated by mechanistic, cell-culture, animal and cosmetic-science work. The most-cited modern review reports gene-expression findings and argues that clinical studies should now be conducted — which tells you they had not been.[1]
Is GHK-Cu in skincare products the same as GHK-Cu sold as a research chemical?
The molecule can be the same; the product, the concentration, the formulation, the route and the quality controls are not. A cosmetic containing copper tripeptide-1 is a regulated consumer product intended for topical use. Vials sold for research use are neither.
Is GHK-Cu FDA approved?
No. It has no approved drug indication. It is lawfully used as a cosmetic ingredient, which is a separate regulatory category that does not involve any efficacy review.

Continue reading

Peptide Science

What Are Peptides?

Peptides are short chains of amino acids. What separates a peptide from a protein, why the body uses them as signals, and why that makes them both useful drugs and difficult ones.

Regulation

Are Peptides FDA Approved?

Some peptides are FDA approved drugs. Most compounds sold as "peptides" are not. Here is how to tell the difference, and what approval does and does not mean.

References

Peptide Insider cites primary sources wherever they exist — regulatory documents, trial registrations and peer-reviewed literature — in preference to secondary summaries.

  1. 1.
    Pickart L, Margolina A. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics, 2018;5(2):29.
    Peer-reviewedDOI: 10.3390/cosmetics5020029

    Open-access review by the peptide’s principal researchers. Read with that affiliation in mind.

  2. 2.
    U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA, 2026;Page last updated 22 April 2026.
    Regulatory